<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158167</url>
  </required_header>
  <id_info>
    <org_study_id>00807</org_study_id>
    <nct_id>NCT04158167</nct_id>
  </id_info>
  <brief_title>Neurobiological Effects of Oxytocin in Schizophrenia - Imaging Study</brief_title>
  <official_title>Neurobiological Effects of Oxytocin on Metacognitive Deficits in Schizophrenia: A Pharmacological - Imaging Genetics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health and Neuro Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health and Neuro Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether 24IU oxytocin can result in changes in functional brain connectivity
      in patients with schizophrenia and healthy individuals using functional magnetic resonance
      imaging (fMRI). The study will also examine the effect of oxytocin receptor gene polymorphism
      on the functional connectivity
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>After completion of clinical and cognitive assessments, all subjects will undergo a baseline fMRI scan. Later subjects will receive24IU oxytocin and saline placebo in counterbalanced order on two separate days and undergo repeat fMRI scans.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fMRI changes with oxytocin</measure>
    <time_frame>Upto 90 minutes after administration</time_frame>
    <description>changes in functional brain connectivity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will receive both oxytocin and placebo in a counterbalanced design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced</description>
    <arm_group_label>oxytocin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion and Exclusion Criteria:

        Schizophrenia subjects:

        Inclusion criteria 1) Males between 18 and 50 years 2) Diagnosis of DSM-IV schizophrenia,
        schizoaffective or schizophreniform disorder 3) capacity to provide informed consent, as
        evaluated by the MacArthur Competence Assessment Tool for Clinical Research Exclusion
        criteria

          1. General impairment in intellectual functioning

          2. History of alcohol or substance dependence in the last 12 months (with the exception
             of nicotine)

          3. Contraindication to oxytocin like hypersensitivity, vascular disease, chronic
             nephritis, epilepsy, asthma

          4. Past history of head injury resulting in loss of consciousness or neurosurgery

          5. Concomitant severe medical conditions

          6. Metal implants or paramagnetic objects within the body or claustrophobia which may
             interfere with the MRI.

        Healthy volunteers:

        Inclusion criteria

          1. Males between 18 and 50 years

          2. Capacity to provide informed consent Exclusion criteria

        1) Life-time diagnosis of psychiatric illnesses including substance abuse 2) General
        impairment in intellectual functioning 3) Past history of head injury resulting in loss of
        consciousness or neurosurgery 4) Concomitant severe medical or neurological conditions 5)
        Metal implants or paramagnetic objects or claustrophobia 6) Family history of
        schizophrenia, schizoaffective or schizophreniform disorder in family member (sibling,
        parent or offspring) 7) Contraindication to oxytocin like hypersensitivity, vascular
        disease, chronic nephritis, epilepsy, asthma.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Mental Health and Neurosciences</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health and Neuro Sciences, India</investigator_affiliation>
    <investigator_full_name>Dr Naren P Rao</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

